Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $21.40 Average Price Target from Analysts

Cellebrite DI Ltd. (NASDAQ:CLBT) has earned a consensus recommendation of “Moderate Buy” from the six research firms that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $21.80.

A number of research analysts have recently commented on CLBT shares. Needham & Company LLC dropped their price target on Cellebrite DI from $18.00 to $15.00 and set a “buy” rating for the company in a research note on Friday, May 15th. DA Davidson boosted their price objective on Cellebrite DI from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings raised Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $15.25 on Thursday. The company has a market cap of $3.80 billion, a price-to-earnings ratio of 54.47, a PEG ratio of 1.99 and a beta of 1.18. The firm has a 50 day simple moving average of $14.59 and a 200 day simple moving average of $14.09. Cellebrite DI has a one year low of $11.02 and a one year high of $19.98.

Insider Buying and Selling

In other news, CFO David Barter sold 41,734 shares of the business’s stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $16.38, for a total value of $683,602.92. Following the transaction, the chief financial officer owned 334,219 shares in the company, valued at approximately $5,474,507.22. The trade was a 11.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas E. Hogan sold 103,188 shares of the company’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the sale, the chief executive officer directly owned 590,777 shares in the company, valued at approximately $9,310,645.52. This represents a 14.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 157,580 shares of company stock valued at $2,471,488 over the last 90 days. 5.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Cellebrite DI

Several hedge funds and other institutional investors have recently bought and sold shares of CLBT. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Cellebrite DI by 16.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 173,013 shares of the company’s stock valued at $3,362,000 after purchasing an additional 24,881 shares during the period. Geode Capital Management LLC grew its stake in Cellebrite DI by 16.2% during the second quarter. Geode Capital Management LLC now owns 314,440 shares of the company’s stock worth $5,029,000 after purchasing an additional 43,898 shares during the period. Invesco Ltd. grew its stake in Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock worth $56,089,000 after purchasing an additional 209,473 shares during the period. First Trust Advisors LP bought a new stake in Cellebrite DI in the second quarter worth approximately $341,000. Finally, Marshall Wace LLP bought a new stake in Cellebrite DI in the second quarter worth approximately $4,472,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.